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Abstract
Tissue inhibitors of matrix metalloproteinases (TIMPs) regulate
the breakdown of extracellular matrix components and play an
important role in tissue remodelling and growth, in both
physiological and pathological conditions. We studied the
autoimmune response to TIMPs in patients with rheumatoid
arthritis (RA). Eighty-nine paired blood and synovial fluid
samples from patients with RA were assessed for their reactivity
with recombinant tissue inhibitors of metalloproteinases (TIMPs)
1 to 4 by an ELISA and were compared with blood from 62
healthy controls and 21 synovial fluid samples from patients with
degenerative joint diseases. Presence of antibodies was
established as the absorbance of the sample more than 2
standard deviations above the mean of the controls. In addition,
immunoglobulin G (IgG) from blood samples of RA patients
possessing TIMP antibodies was isolated on protein A–
sepharose and tested for the in vitro ability to neutralize TIMP-2-
dependent effects on metalloproteinase 9 (MMP9). Anti-TIMP
antibodies were found in 56% of RA samples but in only 5% of
the controls (P < 0.005). RA patients had high frequencies of
antibodies against all TIMPs except TIMP-3. TIMP-2 antibodies
were most frequently found (33%), being significantly more
prevalent (P = 0.024) in patients with nonerosive than erosive
RA. TIMP-1 antibodies were significantly more often found in
synovial fluid samples than in the matched blood samples (P <
0.025). Importantly, the IgG fraction containing TIMP antibodies
down-regulated the TIMP-2 inhibitory effect, thereby supporting
MMP9 activity in vitro. In the present study, we show that RA
patients frequently develop autoimmune response to TIMPs that
may act as a functionally significant regulator of MMP activity
and thereby of joint destruction.
Introduction
The matrix metalloproteinases (MMPs) are a family of zinc-
dependent endopeptidases regulating the breakdown of
extracellular matrix and are thereby essential for physiological
processes of embryonic development, morphogenesis, and
tissue remodelling and resorption, but are also of crucial
importance for pathological conditions including inflammation,
tumour growth, and metastasis [1-3]. Extracellularly, the activ-
ity of MMPs is regulated by their endogenous inhibitors, tissue
inhibitors of metalloproteinases (TIMPs) [4]. The TIMP family
known at present consists of four distinct members (TIMPs 1
to 4) (Table 1). All of these except TIMP-4 are expressed in
most tissues and body fluids. TIMP-4 has a tissue-specific dis-
tribution, being localized in brain, striated muscles, and ova-
ries. The expression of TIMPs is typically induced by external
stimuli such as certain inflammatory cytokines (IL-6, IL-1β ) and
by certain growth factors.
Extracellularly, TIMPs inhibit MMP activity by forming high-
affinity noncovalent complexes with MMPs. The amino-termi-
nal domain of TIMP binds the active site of MMPs, inhibiting
their proteolytic activity. The carboxy-terminal domain of cer-
tain TIMPs has also the ability to form complexes with proen-
zymes (proMMPs) regulating the MMP activation process [4].
The balance between the inhibitory and activating properties
of TIMP-1 and TIMP-2 defines their specificity regarding differ-
ent MMPs. However, certain differences in TIMPs' specificities
have been recognized. Indeed, TIMP-1 is a preferential inhibi-
tor of soluble MMPs, while TIMP-2 and TIMP-3 are also effi-
cient inhibitors of the membrane-bound MMPs. TIMP-3
DMARD, disease-modifying antirheumatic drug; ELISA = enzyme-linked immunosorbent assay; Ig, immunoglobulin; IL, interleukin; MAPK = mitogen-
activated protein kinase; MMP, matrix metalloproteinase; MTX, methotrexate; PBS, phosphate-buffered serum; PVDF, polyvinylidene fluoride; RA, 
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stretches its inhibitory activity to include, besides MMPs, also
some members of the ADAMTS (a disintegrin and metallopro-
teinase with thrombospondin motifs) family, inhibiting aggre-
canases and TNF-α -converting enzyme. Although TIMP-
dependent inhibition of MMPs is the most-studied property of
TIMPs, other, unexpected functions of these proteinases have
been recently recognized. TIMPS have been shown to stimu-
late cell proliferation participating in mitosis and tissue differ-
entiation, to regulate cell survival and apoptosis, and to inhibit
angiogenesis. The latter functions of TIMPs seem to be real-
ized through receptor-mediated intracellular signalling rather
than by the inhibition of MMPs.
An important role of the MMP/TIMP system in the develop-
ment and progression of rheumatoid arthritis (RA) has been
repeatedly proved in clinical studies. Patients with RA have
increased levels of MMPs, which are significantly higher
locally, in synovial tissues, than in the circulation [5-7]. Indeed,
TIMPs are abundantly expressed in inflamed synovia during
RA. Importantly, high levels of MMPs have predictive value for
the development of joint erosions in the early stage of RA [8-
10]. Treatment with antirheumatic drugs and clinical remission
of RA are associated with down-regulation of the expression
of MMPs in the synovial lining layer [5,11,12]. However, TIMP
levels were not readily modified in the course of treatment
[11].
In the present study, we demonstrate that TIMPs trigger
autoantibody production in a great majority of the patients with
RA. These autoantibodies display TIMP-neutralizing properties
and thereby modulate MMP9 activity. Finally, the presence of
TIMP-specific autoimmunity is associated with a nondestruc-
tive course of RA.
Materials and methods
Patients and controls
Plasma and synovial fluid samples were collected from 89 RA
patients with joint effusion who attended the rheumatology
clinics at Sahlgrenska University Hospital in Göteborg (Table
2). All the patients had a diagnosis of RA and fulfilled the
revised criteria of the American College of Rheumatology [13].
The study was approved by the Ethics Committee of Sahlgren-
ska University Hospital and informed consent was obtained
from all the patients. At the time of synovial fluid and blood
sampling, all the patients were receiving nonsteroidal anti-
inflammatory drugs. Disease-modifying antirheumatic drugs
(DMARDs) were being used by 47 patients, of whom 31 were
using methotrexate. In 6 patients, methotrexate was being
used in combination with biological agents (infliximab, 4;
etanercept, 2). Sixteen patients were using DMARDs other
than methotrexate (gold salts, 5; azathioprine, 2; sulfasalazine,
5; ciclosporin, 4; leflunomide, 2). A combination of two or
more DMARDs was being used by 6 patients. The remaining
42 patients were receiving no DMARD treatment at the time of
blood and synovial fluid sampling. Recent radiographs of the
hands and feet were obtained for all the patients. The pres-
ence of bone erosions, defined as the loss of cortical definition
at the joint, was recorded in proximal interphalangeal, metacar-
pophalangeal, carpal, and metatarsophalangeal and inter-
phalangeal joints of forefeet. The presence of a single erosion
was sufficient to fulfil the requirement of an erosive disease.
The presence of rheumatoid factor of any of the immunoglob-
ulin isotypes was considered positive.
Blood samples from 62 healthy controls (aged 18 to 67 years)
were used in the control group (Table 2). Control synovial fluid
was obtained from 21 patients (aged 36 to 88 years) with
noninflammatory joint diseases (osteoarthritis, 8 patients;
chondrocalcinosis, 2; villonodular synovitis, 1; knee contusion,
4; rupture of meniscus, 4; and rupture of cruciate ligament, 2).
Table 1
Functional properties of the tissue inhibitors of metalloproteinases (TIMPs) (based on reviews [1-4])
Property TIMP-1 TIMP-2 TIMP-3 TIMP-4
Approximate protein size 28 kDa 21 kDa 24/27 kDa 22 kDa
Localisation Soluble Soluble + cell surface Extracellular matrix Cell surface, tissue-specific
Intracellular activation Receptor(s) Nuclear translocation Receptor(s) No Not known
Proteinase type inhibition Secreted MMP, ADAMTS Secreted MMP, MT-MMP MT-MMP, ADAMTS Secreted MMP, MT-MMP
Apoptosis Inhibits (BCL-2 regulation) Inhibits Promotes (TACE, death receptors) Promotes
Angiogenesis Inhibits Inhibits Inhibits Inhibits
Proliferation Stimulates Stimulates Inhibits Stimulates
Tumour growth Promotes Promotes Inhibits Not known
Knockout mice Resistance to Pseudomonas 
infection
Impaired pro-MMP2 activation Lung emphysema, chronic hepatitis. 
High TNF-α
Not known
ADAMTS, a disintegrin and metalloproteinase domain with thrombospondin motifs; MMP, matrix metallproteinase; MT-MMP, membrane-type matrix 
metalloproteinase; TACE, tumour-necrosis-factor-α -converting enzyme; TIMP, tissue inhibitor of metalloproteinases; TNF, tumour necrosis factor.Available online http://arthritis-research.com/content/7/5/R1014
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Synovial fluid was obtained by arthrocentesis, aseptically aspi-
rated, and transmitted into tubes containing sodium citrate
(0.129 mol/l; pH 7.4). All synovial fluid samples were obtained
from knee joints. At the same time, blood samples were
obtained from the cubital vein and directly transferred into
sodium citrate medium. Collected blood and synovial fluid
samples were centrifuged at 800 g for 15 min, divided into
aliquots, and stored frozen at -20°C until use.
Laboratory parameters of disease activity
Serum levels of C-reactive protein were measured with a
standard nephelometric assay with established normal range
0 to 5 mg/l. The erythrocyte sedimentation rate was measured
by the Westergren method (normal range, 0 to 20 mm/hour).
White blood cell counts in blood and in synovial fluid were
done using an F300 microcell counter (Sysmex, Toa, Japan).
Synovial fluid samples were treated with hyaluronidase before
the cell count.
Detection of antibodies to TIMP
The reactivity of patient blood and synovial fluid samples with
TIMPs was determined by ELISA. Briefly, 96-well polystyrene
dishes (Nunc, Roskilde, Denmark) were coated with human
recombinant TIMPs (R&D Systems, Abingdon, UK). Individual
preparations of TIMP-1, TIMP-2, TIMP-3, and TIMP-4 were
reconstituted in PBS to 0.5 µg/ml, and 50 µl of the solution
was introduced into each well and left overnight at room tem-
perature. After washing with PBS containing 0.1% Tween-20,
plates were blocked with 1% ovalbumin (Sigma, St Louis, MO,
USA) in PBS for 2 hours at room temperature. Matched sam-
ples of plasma and synovial fluid were introduced into the par-
allel strips, diluted 1:100 in 1% ovalbumin. Horseradish-
peroxidase-labelled detection antibodies (rabbit F(ab')2-anti-
human immunoglubulin (Ig)G and IgM; DAKO A/S, Glostrup,
Denmark), ExtrAvidin peroxidase conjugate (Sigma) and corre-
sponding substrate were used for colour development. The
absorbance reading at 450 nm was recorded. The absorb-
ances of the patient samples were compared with the mean
values obtained in the control group of healthy individuals.
Patient samples with absorbance more than 2 standard devia-
tions (SDs) above the mean of the control samples of blood (n
= 62) and synovial fluid (n = 21) were considered positive for
the antibodies against the given TIMP. Among the control
groups, the frequency of samples with absorbance values
above 2 SD was low and ranged from 0% to 6%. The samples
of the control groups within 2 SD demonstrated a bimodal
distribution.
Purification of immunoglobulins
Four serum samples were selected from RA patients, two of
which contained antibodies against TIMPs and the other two
in which no antibodies to any of the TIMPs were found. IgG
from these four patients was purified by affinity chromatogra-
phy using HiTrap Protein A columns (Amersham Biosciences,
Uppsala, Sweden), in accordance with the manufacturer's
instructions. Briefly, 1 ml of a serum was diluted in sodium
phosphate binding buffer (20 mM, pH 7.0) and loaded on the
column. The column was washed with 10 volumes of the bind-
ing buffer and the bound IgG was eluted with 5 ml 0.1 M citric
acid (pH 3.3). The collected IgG fractions were immediately
Table 2
Characteristics of patients with rheumatoid arthritis and of controls
Characteristic RA patients Controlsa
Total (n = 89) Erosive RA (n = 46) Nonerosive RA (n = 43) Serum (n = 62) Synovial fluid (n = 21)
Age, years 58 ± 2 62 ± 1.8 54 ± 3.1** 52 ± 1.4 64 ± 2
Gender, F/M 60/29 29/17 31/12 46/16 12/9
Erosivity 46/89 46 0
No. (%) RF+ 51 41 (89%) 10 (23%)***
Disease duration, years 11 ± 1.3 13 ± 1.3 8.2 ± 1.3*
No. (%) with disease duration <3 years 27 (30%) 9 (20%) 18 (42%)
CRP, mg/l 40 ± 8 42 ± 7 36 ± 7
WBC count Blood 
                 Synovial fluid
7.7 ± 2.2
13 ± 3.5
8.0 ± 0.4
14.3 ± 3.4
7.1 ± 0.4
12.6 ± 2.3
Synovial fluid 13 ± 3.5 14.3 ± 3.4 12.6 ± 2.3
No. (%) DMARD-treated 47 (53%) 36 (76%) 11 (26%)
Methotrexate 31 25 6***
Other 16 11 5
Values are means ± standard errors of the mean unless otherwise indicated.
aControls were healthy subjects or patients with degenerative or traumatic joint disease. *P = 0.0047; **P = 0.0014; ***P > 0.0001. CRP, C-
reactive protein; DMARD, disease-modifying antirheumatic drug; F, female; M, male; RF, rheumatoid factor; WBC, white blood cell.Arthritis Research & Therapy    Vol 7 No 5    Bokarewa et al.
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neutralized with 1 M Tris/HCl (pH 9.0) and dialysed against
the binding buffer at 4°C overnight. The protein concentration
of the eluted immunoglobulins was estimated using Bradford
reagent.
Western blot analysis
Cell lysates of THP-1 (a human monocytic cell line) and H9 (a
human T-cell lymphoma) were separated on SDS–PAGE
(18% Tris-glycine gel; Novex, Invitrogen, Lidingö, Sweden)
and transferred to a polyvinylidene fluoride (PVDF) membrane
in a Mini-Trans-Blot electrophoretic unit (Bio-Rad Laborato-
ries, Sundbyberg, Sweden) using Tris-glycine buffer (pH 8.3)
containing 20% methanol. The PVDF membrane was washed
and blocked with 2% fat-free milk. After washing, the mem-
brane was incubated with IgG fractions obtained from serum
highly reactive with TIMP-2 (diluted 1:40). Interaction between
TIMP blotted to the PVDF membrane and human IgG was vis-
ualized using horseradish-peroxidase-labelled antibodies (rab-
bit F(ab')2-antihuman IgG; DAKO), and aminoethylcarbazole
substrate in sodium acetate buffer (pH 5.5). A membrane blot-
ted with anti-TIMP-2 mouse monoclonal antibodies (Santa
Cruz Biotechnology, Santa Cruz, CA, USA) was used as a
positive control.
Neutralization of TIMP-2 activity by antibodies from RA 
patients
The functional activity of IgG from RA patients against TIMP
was assessed by incubating TIMP-2 (2.5 ng) with increasing
amounts (0 µg to 100 µg) of IgG (see above) in Tris/HCl
buffer (50 mM, pH 7.6, containing 1.5 mM NaCl, 0.5 mM
CaCl2, 1 µM ZnCl2, and 0.01% BRIJ 35 for 2 hours at room
temperature. After incubation, the immunoglobulin/TIMP-2
mixtures were then added to MMP9 (32 ng/ml) and activated
with 1 mM p-aminophenylmercuric acid. The residual activity of
MMP9 was assessed by Biotrak activity assay (Amersham)
and registered colorimetrically by hydrolysis of S-2444 sub-
strate at 405 nm. The absorbance values of the mixtures con-
taining immunoglobulin fraction alone, immunoglobulin/TIMP-
2, and TIMP-2 alone were recorded.
Statistical analysis
The matched blood and synovial fluid samples were compared
by paired t-test. For the evaluation of possible influence of radi-
ological changes and ongoing treatment on the TIMP antibody
levels, patient material was stratified accordingly. The differ-
ence between the groups was calculated using the Mann-
Whitney U test. Interrelation between parameters studied was
calculated using the Spearman correlation. For all statistical
evaluations of the results, P values below 0.05 were consid-
ered significant.
Results
Clinical and demographic characteristics of the patients with
RA and the controls are presented in Table 2. Of the eighty-
nine RA patients, 46 had erosive joint disease, and the remain-
ing 43 had no erosions on radiological examination. The
patients with erosive RA were older than those with nonero-
sive RA, had had joint disease for longer, and were more often
positive for rheumatoid factor (Table 2). Most of the patients in
the cohort with erosive RA were receiving DMARDs, whereas
only a minority in the group with nonerosive RA were receiving
DMARDs.
Autoimmune reactivity against TIMPs in patients with RA
Samples of blood and synovial fluid from 89 patients with RA
were tested for the presence of autoantibodies against all four
types of TIMP (TIMP-1, -2, -3, and -4) and compared with the
control blood (n = 62) and synovial fluid (n = 21) samples (Fig.
1). Patient samples with absorbance more than 2 SD above
the mean value of the control samples were considered posi-
tive for the antibodies to the particular type of TIMP tested. The
levels of TIMP antibodies in the blood samples of RA patients
showed a significant correlation with the levels in synovial fluid
(r = 0.45 to 0.52; P < 0.0001) for the antibodies specific for
TIMP-2, -3, and -4. The levels of TIMP-1 antibodies in blood
showed poor correlation with those in synovial fluid (r = 0.13).
The antibodies against at least one of the four TIMPs were
detected in the majority of RA synovial fluid and blood samples
tested (50/89, 56%). The presence of TIMP antibodies was
significantly lower in the control blood samples (5/62, 8%; P
< 0.025) and in synovial fluid samples originating from
patients with degenerative joint diseases (1/21, 5%, P  <
0.0001). The incidence of antibodies against individual types
of TIMP varied considerably. Antibodies specific for TIMP-2
predominated (33%), while the frequency of TIMP-3 antibod-
ies was clearly lower (6/89, 7%). The occurence of antibodies
against two or more different TIMPs was noted in 13/50 RA
patients (26%). Antibodies against TIMP-1 and/or TIMP-2
were detected in 45/50 RA patients (87%), but only two of
these patients had both types of autoantibody. Levels of anti-
bodies to TIMP-1 were correlated with those of antibodies to
TIMP-4 in the blood samples (r = 0.60, P < 0.0001). This was
an exception, since in other cases correlation between autoan-
tibodies to different TIMPs in blood and synovial fluid was not
observed. TIMP-1 antibodies were more prevalent in synovial
fluid than in blood samples (12/89 versus 6/89, P < 0.05).
Interaction of the isolated IgG with TIMP-2 was confirmed by
Western blot analysis (Fig. 2). The immunoglobulins isolated
from a patient with RA having high reactivity with TIMP-2, as
detected by ELISA, recognized a protein of molecular weight
22 kDa corresponding to TIMP-2 forming a band in the blot-
ting membrane.
Relation of TIMP antibodies to clinical features of RA
Antibodies against TIMPs in blood and/or synovial fluid sam-
ples were detected more often in patients with nonerosive RA
(67%) than with erosive RA (43%, P = 0.023) (Fig. 3). This dif-
ference was due in part to the high prevalence of TIMP-2 anti-
bodies in the samples of patients with nonerosive RA (44%Available online http://arthritis-research.com/content/7/5/R1014
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versus 22%, P = 0.024), while the incidence of antibodies to
other TIMPs was similar in erosive and nonerosive RA. Another
reason for the difference is that the combination of antibodies
to more than one TIMP in patients with nonerosive RA was
less frequent than in patients with erosive RA (17% versus
40%, P = 0.048). The frequency with which TIMP antibodies
were present tended to decrease with the duration of RA (≤  3
years, 17/28, 61%; versus >3 years, 31/63, 49%), although
the difference did not achieve statistical significance. The
presence of TIMP antibodies showed no correlation with the
age of the patients or with levels of acute-phase reactants (C-
reactive protein, white blood cell counts). No difference in the
TIMP antibody levels was found in the patients treated with
methotrexate or other DMARDs compared with patients not
treated with DMARDs.
Antibodies from RA patients support metalloproteinase 
activity by neutralizing TIMP-2
The purified IgG fractions originating from two RA serum sam-
ples containing antibodies against TIMPs and from two other
samples lacking antibody activity to any of the TIMPs were
analyzed. Bearing in mind the significant difference in the pat-
tern of erosivity between RA patients with and those without
TIMP-2 specific autoantibodies, we decided to analyse
whether these immunoglobulins supported MMP9 activity by
neutralizing TIMP-2.
Recombinant human MMP9 was activated with p-aminophe-
nylmercuric acid under standard conditions (see Materials and
methods). This activity of MMP9 was set at 100%. Serial
dilutions of recombinant TIMP-2 were assessed with respect
to their effect on MMP9 activity, and the lowest amount of
TIMP-2 totally abolishing the activation of MMP9 was used in
further experiments. This concentration of TIMP-2 was incu-
Figure 1
Autoreactivity against TIMPs in blood and synovial fluid of patients with RA and in controls Autoreactivity against TIMPs in blood and synovial fluid of patients with RA and in controls. Autoreactivity was measured as absorbance at 450 nm. 
White boxes, patients with RA, n = 89; coloured boxes, controls (blood n = 62, synovial fluid n = 21). The box plots represent the means and inter-
quartile ranges in each group. The dashed line indicates the cut-off level for each type of TIMP equal to the mean +2 standard deviations of the con-
trols. TIMP, tissue inhibitor of metalloproteinases.
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bated with increasing concentrations of the IgG fractions. The
ability of TIMP-2/IgG mixtures to prevent the activation of
MMP9 was monitored. In parallel, the effect of IgG fractions on
MMP9 activation was monitored.
At the concentrations used, TIMP-2 totally abolished activation
of MMP9, diminishing hydrolysis of S-2444 substrate from
100% to 7% (Fig. 4, bar 2). In the presence of IgG fractions,
MMP9 activation proceeded undisturbed (Fig. 4, bar 1) com-
pared with that of the MMP9 activation in the presence of the
buffer alone. Mixtures of TIMP-2 with IgG fractions had varia-
ble effect on MMP9 activation (Fig. 4). The IgG fractions con-
taining antibodies against TIMPs neutralized TIMP-2 by
approximately 76% (patient 1, 62%; patient 2, 88%), permit-
ting activation of MMP9. In contrast, IgG fractions from the
controls had significantly less effect on TIMP-2 activity, and
the residual TIMP-2 was sufficient to significantly reduce
MMP9 activation from 100% to 37% (control 1, 10%; control
2, 45%) (Fig. 4, bar 3).
Discussion
The present study demonstrates endogenous autoimmune
reactivity against TIMPs in patients with RA. Indeed, antibod-
ies against at least one of the four TIMPs were found in 56%
of the patient material tested. Strikingly, autoreactivity to TIMP-
2 was associated with a favourable – that is, nonerosive –
course of RA. Importantly, immunoglobulins containing TIMP-
2 antibodies purified from RA patients were proved to be func-
tionally active by preventing in vitro TIMP-2-dependent inacti-
vation of MMP9. Taken together, these observations suggest
a potential protective role of TIMP-specific antibodies in the
development of destructive joint disease. If that is the case, it
would be one of a few examples of protective rather then harm-
ful autoimmunity in RA. This hypothesis seems to conflict with
the present view of MMP-mediated proteolytic degradation of
cartilage in RA and with the fact that TIMP-3-transfected syn-
ovial fibroblasts are deprived of their invasive capacity [14],
while TIMP-1-transduced chondrocytes resist catabolism
[15]. However, it becomes obvious that biological functions of
TIMPs are not restricted to chemical neutralization of MMPs.
Indeed, studies on inhibition of MMPs have shown only a lim-
ited effect on arthritis and inflammation [16,17].
Antibodies against TIMP-1 and TIMP-2 comprised most of the
anti-TIMP directed autoimmunity. These findings are in agree-
ment with previous reports on the constitutive expression of
these two TIMPs in inflamed joint tissues [7,11], indicating
autoantigen-driven B-cell activation. Several functional proper-
ties of TIMPs are of potential importance in the pathogenesis
of arthritis. Overexpression of TIMP-1 and TIMP-2 is associ-
ated with inhibition of apoptosis and invasive tumour growth
[18-20]. In tumours, TIMP-2 is coexpressed with mutant p53
and BCL-2 [19]. Analogous to tumour cells, synovial fibrob-
lasts in RA are characterized by a reduced apoptosis, invasive
properties, and the expression of mutant p53 [21]. The other
common feature for these two types of TIMP is the ability to
induce intracellular signalling. Extracellular stimulation with
TIMP-1 and TIMP-2 is recognized by specific surface recep-
tors and activates cascades dependent on mitogen-activated
protein kinase (MAPK) and on tyrosine kinase [22]. An MAPK-
dependent mechanism is crucial for triggering inflammatory
cytokine production, a potential pathogenic mechanism in RA
[23,24]. A relation between TIMP-2 expression and topoi-
somerase II activity has also been suggested [25]. The impor-
tant role of topoisomerase II in the development of
experimental arthritis has recently been demonstrated [26].
All these experimental data further support our findings on the
immunomodulatory role of antibodies against TIMP-1 and
TIMP-2 in patients with RA. Importantly, we showed that TIMP-
2 antibodies purified from RA patients were functionally active,
since they were able to neutralize TIMP-2-mediated inhibition
of MMP9. In the established experimental system, the neutral-
ization of TIMP-2 with purified IgG interfered with TIMP-2 bind-
ing to the catalytic domain of MMP9. However, an ability of the
TIMP-2 antibodies to inhibit TIMP-dependent activation of
proMMPs was not assessed. Neutralization of MMP-inhibiting
properties of TIMP may change the balance of TIMP effects in
favour of proMMP activation. Taking into consideration that
TIMP-2 functions predominantly as an MMP9 inhibitor
(through its catalytic domain) and a proMMP2 activator
(through its noncatalytic haemopexin domain), the presence of
anti-TIMP-2 antibodies may favour accumulation of functional
MMP2. The beneficial role of MMP2 in the development of
arthritis has been recently suggested in the animal model [27].
The attenuation of TIMP-2 functions in the presence of anti-
TIMP-2 antibodies in RA patients may be one of the steps in
the mechanism preventing joint destruction.
Figure 2
Western blot analysis of anti-TIMP-2 antibodies Western blot analysis of anti-TIMP-2 antibodies. Lysates of THP-1 (a 
human monocytic cell line) and H9 (a human T-cell lymphoma) were 
separated in 18% Tris-glycine gel, transferred into a polyvinylidene fluo-
ride membrane, and blotted with immunoglobulin G (IgG) fractions from 
a patient with rheumatoid arthritis having high levels of anti-TIMP-2 anti-
bodies detected by ELISA. The IgG fraction visualized a band of molec-
ular weight 22 kDa, corresponding to TIMP-2. TIMP, tissue inhibitor of 
metalloproteinases.Available online http://arthritis-research.com/content/7/5/R1014
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Figure 3
Antibodies against TIMPs in patients with erosive or nonerosive rheumatoid arthritis (RA) and in controls Antibodies against TIMPs in patients with erosive or nonerosive rheumatoid arthritis (RA) and in controls. The presence of antibodies against tissue 
inhibitors of metalloproteinases (TIMPs) was defined as absorbance, as measured on ELISA, of (a) blood or (b) synovial fluid samples above 2 
standard deviations of the mean of the control groups consisting of blood donor samples (n = 62) and synovial fluids from patients with joint trauma 
(n = 21). Vertical axes indicate percentage of subjects.
Figure 4
Effect of TIMP-2 antibodies from RA patients on inhibition of MMP9 activity by recombinant TIMP-2 Effect of TIMP-2 antibodies from RA patients on inhibition of MMP9 activity by recombinant TIMP-2. Recombinant matrix metalloproteinase 9 
(MMP9) was incubated with mixtures containing (bar 1)immunoglobulin fractions (50 µg) from rheumatoid arthritis (RA) patients possessing antibod-
ies against tissue inhibitor of metalloproteinases-2 (TIMP-2), (bar 2) recombinant TIMP-2 (2.5 ng), (bar 3) TIMP-2/immunoglobulin of RA patients not 
possessing (n = 2), and (bar 4) possessing TIMP-2 antibodies (n = 2). MMP9 activity was measured as described in Materials and methods. aTIMP, 
immunoglobulin G containing antibodies against TIMP; contr, control; IgG, immunoglobulin G.
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Antibody level specific for TIMP-3 showed the most pro-
nounced rise in samples of RA patients compared with those
from controls (see Fig. 1). However, patients with high titres of
TIMP-3 antibodies did not differ in any of the clinical aspects.
TIMP-3 exerts a broad inhibition profile, controlling the activity
of MMPs and aggrecanases. It has been also recognized as a
potent regulator of TNF-α  levels, inhibiting the generation of
soluble TNF-α  by the TNF-α -converting enzyme [28]. Taking
into consideration increased levels of TNF-α  in patients with
RA and the obvious effect of TNF-α  neutralization for the alle-
viation of arthritis, our finding of a low incidence of antibodies
against TIMP-3 is unexpected. One possible explanation is
that TIMP-3 is bound to the molecules of the extracellular
matrix and is not exposed to B cells in circulation or in the joint
cavity. This might affect efficient antigen presentation and
thereby antibody production. The other possibility is a relative
TIMP-3 deficiency in RA patients due to intra-articular overex-
pression of TNF-α . Unfortunately, information regarding levels
of TIMP-3 in arthritic joints is not available.
Conclusion
We believe that the results presented in this paper clearly indi-
cate that autoimmune responses to TIMP exist in patients with
RA. Future studies will hopefully clarify the in vivo pathogenic
potential of this type of responsiveness.
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